City Therapeutics Inc. (CTY) Financial Statements

Income statement

Metric	TTM	2019	2018	2017	2016
Revenue
Total Revenue	6.5B	8.2B	8.5B	8.6B	8.9B
Cost of Revenue	2.2B	2.4B	2.8B	2.9B	2.9B
Gross Profit	4.3B	5.7B	5.7B	5.7B	6.0B
Operating Expenses
R&D Expense	—	—	—	—	—
SG&A Expense	(1.7B)	659.0M	799.0M	925.0M	1.0B
General & Admin Expense	627.0M	659.0M	799.0M	925.0M	1.0B
Selling & Marketing Expense	1.2B	—	—	—	—
Other Expenses	—	—	5.0B	5.3B	5.6B
Total Operating Expenses	(1.7B)	659.0M	5.8B	6.2B	6.6B
Cost and Expenses	5.6B	5.3B	8.6B	9.1B	9.5B
Operating Income (EBIT)	2.8B	2.9B	2.7B	2.3B	2.3B
Non-Operating
Interest Income	—	—	—	—	—
Interest Expense	(191.0M)	—	448.0M	465.0M	478.0M
Net Interest Income	—	—	—	—	—
Other Non-Op Income/Expense	(403.0M)	(416.0M)	(501.0M)	(522.0M)	(559.0M)
Non-Operating Income (excl Interest)	399.0M	—	53.0M	57.0M	81.0M
EBT (Pre-Tax Income)	2.4B	2.5B	2.2B	1.8B	1.8B
Income Tax Expense	633.0M	641.0M	494.0M	134.0M	678.0M
Bottom Line
Net Income	1.8B	1.8B	1.7B	1.7B	1.1B
Earnings from Cont. Ops	1.8B	1.8B	1.7B	1.7B	1.1B
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	1.8B	1.8B	1.7B	1.7B	1.1B
Per Share
Basic EPS	$0.00	$0.00	$0.00	$0.00	$0.00
Diluted EPS	$0.00	$0.00	$0.00	$0.00	$0.00
Revenue Per Share	—	—	—	—	—
Shares
Basic Shares Outstanding	—	—	—	—	—
Diluted Shares Outstanding	—	—	—	—	—
Profitability Metrics
EBITDA	3.6B	3.8B	4.0B	3.8B	3.9B
D&A	1.3B	1.4B	1.4B	1.6B	1.7B
EBIT	975.0M	—	2.6B	2.3B	2.2B

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2020